The Free Financial Advisor

You are here: Home / Archives for CMS

Florida Health System Agrees to $541.5 Million Settlement Over Medicare Advantage Diagnosis Codes

by Leave a Comment

Medicare Advantage diagnosis codes
A $541.5 million federal settlement involving The Villages Health System highlights how diagnosis codes can affect Medicare Advantage payments. The Justice Department says the settlement resolves allegations and does not constitute a determination of liability. Anatoliy Cherkas/Shutterstock

A Florida healthcare provider has agreed to a massive $541.5 million settlement with the federal government over allegations that unsupported diagnosis codes helped drive up Medicare Advantage payments.

The Villages Health System LLC (TVH), headquartered in The Villages, Florida, agreed to resolve False Claims Act allegations involving diagnosis codes submitted between 2020 and 2024, the U.S. Department of Justice announced August 26.

The case involves a part of Medicare Advantage that most beneficiaries rarely see: the system used to adjust how much the federal government pays private insurers based partly on the health conditions of their members.

Importantly, the settlement resolves allegations, and the Justice Department said there has been no determination of liability.

Why Diagnosis Codes Can Change Medicare Advantage Payments

Medicare Advantage, also known as Medicare Part C, allows beneficiaries to receive Medicare coverage through private insurance plans rather than Original Medicare.

The Centers for Medicare & Medicaid Services pays Medicare Advantage Organizations, or MAOs, a monthly amount for each enrolled beneficiary. Those payments are adjusted for factors affecting expected healthcare costs, with plans generally receiving more money for beneficiaries expected to have greater medical needs. Medical diagnosis codes play a significant role in those calculations.

According to DOJ, diagnoses used for these risk adjustments must be supported by medical records from qualifying patient-provider encounters. For outpatient care, the diagnoses also must have required or affected the patient’s care, treatment, or management during the visit.

That creates an important safeguard: a diagnosis submitted for payment purposes isn’t supposed to exist merely as a code on a patient’s chart. It must meet Medicare’s requirements.

What the Government Alleged The Villages Health Did

Federal officials alleged that from 2020 through 2024, TVH knowingly submitted false diagnosis codes to several Medicare Advantage insurers.

According to DOJ, some of the diagnoses did not have adequate support in patients’ medical records. Others allegedly relied on amendments that weren’t initiated by the treating provider, weren’t made in a timely manner, or weren’t approved by that provider.

The government alleges those codes were then submitted by the Medicare Advantage insurers to CMS, resulting in inflated federal payments. TVH’s payments were also allegedly increased as a result.

The Medicare Advantage organizations involved were Humana, several UnitedHealthcare entities, and GuideWell companies including Blue Cross and Blue Shield of Florida and Florida Blue Medicare.

The Health System Reported the Problem Itself

There is an unusual and important detail in this case: TVH disclosed the coding issue to the government.

On December 27, 2024, the organization made a submission through the Department of Health and Human Services Office of Inspector General’s Health Care Fraud Self-Disclosure Protocol. TVH disclosed that it had submitted invalid diagnosis codes for certain Medicare Advantage beneficiaries and that those codes had increased CMS payments to insurers.

DOJ said TVH subsequently took remedial action, provided the government with a detailed written disclosure, and cooperated with investigators.

Those actions mattered when the settlement was negotiated.

Assistant Attorney General Brett A. Shumate said the resolution demonstrates that the government will pursue organizations accused of inflating Medicare payments while also giving credit to organizations that self-disclose problems, take corrective action and cooperate with investigations.

Acting Deputy Inspector General for Investigations Miranda L. Bennett similarly said TVH’s use of the self-disclosure process and its cooperation were important factors in resolving the matter.

What Happens to the Medicare Advantage Overpayments?

The settlement isn’t limited to TVH.

DOJ said the Medicare Advantage insurers that received payments connected to the invalid diagnosis codes are returning overpayments to the federal government.

Depending on the insurer, that is occurring through deletion of invalid diagnosis codes and/or agreements with DOJ and CMS to return money.

That distinction is important because CMS initially paid the Medicare Advantage organizations. TVH allegedly benefited because provider groups can have arrangements under which their compensation is tied to some portion of the Medicare Advantage payments insurers receive.

In other words, the coding at issue could affect payments at multiple points in the Medicare Advantage system.

The Settlement Comes During TVH’s Bankruptcy Case

The resolution also comes against the backdrop of a major financial restructuring.

TVH filed for Chapter 11 bankruptcy protection on July 3, 2025, in the U.S. Bankruptcy Court for the Middle District of Florida. The bankruptcy court approved the federal settlement on August 25, 2026, one day before DOJ publicly announced it.

Bankruptcy court records also show orders approving settlement agreements involving the United States, Florida Blue and UnitedHealthcare on August 25.

The $541.5 million settlement therefore represents part of a much broader financial situation surrounding the healthcare organization.

What This Means for Medicare Advantage Beneficiaries

For beneficiaries, the announcement does not mean that everyone treated by TVH received an incorrect medical diagnosis, nor does it mean Medicare Advantage members need to repay the $541.5 million themselves.

The government’s allegations concern diagnosis codes used in Medicare Advantage risk-adjustment payments.

However, patients should generally review their medical records and Medicare information and raise questions when they see diagnoses, services or claims they don’t recognize. Accurate health records matter beyond billing because medical information can influence future treatment and communication among healthcare providers.

Anyone who suspects Medicare fraud can report concerns to HHS-OIG. DOJ notes that reports of potential healthcare fraud, waste or abuse can be submitted through the inspector general or by calling 800-HHS-TIPS (800-447-8477).

A $541.5 Million Reminder That Medical Coding Has Real Financial Consequences

A diagnosis code can look like a small administrative detail, but Medicare Advantage’s risk-adjustment system can attach substantial financial consequences to the medical conditions reported for beneficiaries.

The Villages Health System settlement demonstrates the scale those consequences can reach when federal officials allege that unsupported diagnoses have influenced payments over several years.

At the same time, TVH’s voluntary disclosure is an important part of the story. Federal officials specifically credited the organization for reporting the issue, taking remedial measures and cooperating with the investigation.

The case ultimately resolves allegations involving hundreds of millions of dollars in Medicare Advantage payments, but DOJ emphasizes that the settlement is not a judicial determination that TVH was liable for the alleged conduct.

Have you ever found a diagnosis or medical service in your health records that you didn’t recognize? Share your experience in the comments.

What to Read Next

At 55, Should You Still Be Investing Like You’re 35?

At What Point Does Saving More for Retirement Stop Improving Your Life?

Your Advisor Recommends an Annuity. Ask These Questions Before You Say Yes.

CMS Final Rule Ends Federal Medicaid and CHIP Funding for Certain Gender-Transition Care for Minors

by Leave a Comment

Medicaid gender-transition care rule
The Centers for Medicare & Medicaid Services has finalized a rule prohibiting federal Medicaid and CHIP funding for certain gender-transition procedures for minors, with the rule taking effect October 13, 2026. Tada Images/Shutterstock

The Centers for Medicare & Medicaid Services (CMS) has issued a final rule prohibiting the use of federal Medicaid and Children’s Health Insurance Program (CHIP) funds to pay for what the rule terms “sex-rejecting procedures” for minors, according to an official announcement published in the Federal Register on August 13, 2026.

What the New Medicaid and CHIP Rule Prohibits

Under the rule, state Medicaid plans must include provisions barring payment for such procedures for individuals under age 18, while separate state CHIP plans must bar payment for individuals under age 19. The age difference reflects the existing age boundaries of the two programs — Medicaid covers children under 18 in this context, while separate CHIP programs extend coverage to children under 19.

The rule takes effect on October 13, 2026, giving states approximately two months to update their Federally approved state plans to comply with the new requirements.

A limited transition provision is included for beneficiaries already receiving cross-sex hormone therapy at the time the rule takes effect. State Medicaid and CHIP agencies may continue to claim federal matching funds — known as Federal Financial Participation — for those hormone therapy medications for up to six months from the rule’s effective date. After that window closes, federal funding for such treatments would no longer be available under either program.

What the Rule Means for State Medicaid and CHIP Programs

The rule amends 42 CFR Parts 441 and 457, which govern Medicaid and CHIP benefits and state plan requirements. Because Medicaid and CHIP are jointly funded and administered by states and the federal government, states that do not update their plans to conform with the prohibition risk losing federal matching payments for the affected services.

Medicaid and CHIP together provide health coverage to millions of low-income children and families across the country. States set their own eligibility standards and benefits packages, but must operate within federal statutory and regulatory boundaries. Federal matching payments to states are calculated using the Federal Medical Assistance Percentage for Medicaid and an enhanced rate for separate CHIP programs.

Families Should Check How Their State Will Implement the Change

Families whose children currently receive affected care through Medicaid or CHIP should contact their state program to determine how the rule will be implemented and whether their coverage will change. The federal rule takes effect October 13, while a limited six-month transition applies to federal matching funds for certain hormone therapy already being provided when the rule takes effect.

What to Read Next

SEC Approves More Weekday Expirations for Options on Qualifying ETFs

CMS Issues Technical Correction to 2027 Affordable Care Act Benefit and Payment Parameters Rule

CISA Warns of High-Severity Path Traversal Vulnerability in Rockwell Automation ThinManager, Urges Immediate Patching

CMS Issues Technical Correction to 2027 Affordable Care Act Benefit and Payment Parameters Rule

by Leave a Comment

CMS technical correction
CMS has published a technical correction to the 2027 Affordable Care Act Benefit and Payment Parameters rule, clarifying regulatory language for insurers and Marketplace administrators without changing the underlying policy. Andrii Yalanskyi/Shutterstock

The Centers for Medicare & Medicaid Services (CMS) has issued a technical correction to its 2027 Notice of Benefit and Payment Parameters, updating portions of the Affordable Care Act (ACA) rule that governs health insurance marketplaces and the Basic Health Program. The correction was published in the Federal Register on July 21, 2026, but became effective July 20, 2026, according to CMS. Officials described the action as a technical fix that corrects errors in both the explanatory preamble and the regulatory text of the previously published final rule. The correction does not introduce new policy changes but ensures the rule accurately reflects CMS’s intended language.

What the Correction Means

The technical correction applies to regulations under 42 CFR Part 600 and 45 CFR Parts 150, 155, and 156, which establish standards for Affordable Care Act Marketplace plans and the Basic Health Program. The original 2027 rule affects health insurers, state and federally facilitated marketplaces, and consumers who purchase ACA-compliant health coverage. CMS said the correction addresses drafting errors identified after publication of the final rule, a routine step agencies sometimes take to clarify regulatory language without changing the underlying policy. Because the revisions are technical in nature, CMS waived additional notice-and-comment procedures and the usual delay before the correction took effect.

Who Should Pay Attention?

Most consumers are unlikely to notice an immediate impact from the correction itself. However, insurers, state marketplace administrators, compliance professionals, and organizations involved in ACA Marketplace operations should review the updated regulatory language to ensure they are following the corrected requirements. Anyone seeking detailed information about the revisions should consult the official Federal Register notice or CMS guidance, as the technical correction does not provide an extensive explanation of every change.

What to Read Next

DOJ Settles for $400 Million with Alaska Native Tribal Health Consortium Over Unpaid Healthcare Administrative Costs

HHS Seeks OMB Approval for Children and Families Program Monitoring Data Collection

Celsius Network Founders Ordered to Pay $16.5 Million to Resolve FTC Charges

Why Prior Authorization Denials Are Up — and Which Patients Are Hit the Hardest

by Leave a Comment

Why Prior Authorization Denials Are Up — and Which Patients Are Hit the Hardest
Image Source: Unsplash.com

You wake up feeling sick, you call the doctor, and you hear something that sounds more frustrating than the illness itself: “We need prior authorization first.” That one sentence can turn a simple treatment plan into paperwork, waiting, and uncertainty. Medical care should move fast when someone is hurting, but the machinery of insurance approval often moves like a slow train stuck in morning traffic. Across hospitals, clinics, and patient support forums, people are talking about a rise in prior authorization denials, and the trend feels louder every year.

Health systems and policy groups keep watching the numbers. Some industry analyses show prior authorization denial rates rising in certain payer populations over recent reporting periods. The exact figure shifts depending on the data source and insurance category, yet the direction stays the same. The growing administrative pressure sits right between doctors trying to deliver care and insurers trying to control cost exposure.

The Paperwork Wave That Keeps Growing Bigger

Healthcare has always carried paperwork, but modern prior authorization systems add another layer of complexity to clinical care. The idea behind prior authorization sounds reasonable on paper: insurance companies review certain treatments before payment happens to make sure the therapy is medically necessary and cost effective. In reality, the process often stretches into long approval chains, multiple phone calls, and repeated documentation requests that slow down treatment decisions.

Reports show prior authorization requests keep growing because newer specialty drugs, imaging procedures, and biologic therapies enter the market every year. Advanced treatments often carry high price tags, so insurers try to screen them before coverage approval. The challenge comes when screening systems become overcautious or inconsistent. Physicians report situations where they submit detailed clinical notes but still receive denial notices that request more supporting information without clearly stating what information remains missing.

Why this Conversation Keeps Showing Up in Reports

Health policy researchers keep discussing increases in denial activity because multiple data streams point in that direction. Some payer networks report tightening authorization criteria, especially for expensive specialty medications and imaging services. The trend becomes noticeable in commercial insurance segments and certain government-sponsored programs.

The Centers for Medicare & Medicaid Services requires prior authorization review for selected services to control unnecessary spending. While the policy goal focuses on reducing waste, healthcare providers sometimes argue that the rules generate unexpected administrative friction. Insurers counter that authorization programs protect patients from unproven or low-value interventions.

Industry data also show automation changes. Some insurance organizations deploy digital decision tools that evaluate clinical submissions using structured criteria. While automation promises faster review, it sometimes produces rigid decision outcomes when clinical nuance exists. Doctors report cases where treatment fits patient needs but fails algorithmic thresholds because the patient’s medical story does not match simplified rule sets.

Patients Who Carry the Heaviest Burden Feel the Wait the Most

Not every patient experiences prior authorization pressure equally. People receiving specialty care, mental health treatment, or chronic disease management encounter more authorization hurdles. Oncology drugs, autoimmune therapy, and advanced imaging procedures frequently trigger review requirements.

Data patterns show lower-income populations experience greater disruption when authorization delays occur because missed work time, transportation costs, and follow-up appointment scheduling become harder to manage. People living in medically underserved regions also face longer turnaround times since specialty reviewers may not operate locally.

Chronic disease patients experience unique stress because treatment interruption can produce symptom rebound. Someone managing diabetes complications, neurological conditions, or inflammatory disease cannot always wait weeks for medication approval. Treatment gaps sometimes lead to emergency visits, and emergency care costs far more than preventive therapy.

Doctors Are Fighting the Clock as Much as They Fight Disease

Physicians describe prior authorization work as invisible labor. The clinical world celebrates surgical success, accurate diagnosis, and lifesaving therapy, but nobody puts authorization negotiation on a medical award stage. Yet clinicians spend time explaining why treatment makes medical sense.

Doctors suggest several practical improvements. Standardizing clinical criteria across insurers would reduce repeated documentation requests. Allowing multi-visit or multi-treatment approvals for chronic disease management would help patients maintain therapy continuity. Expanding real-time clinical decision review tools could shorten approval cycles.

Healthcare teams also encourage patients to ask their doctors whether alternative treatments exist that carry lower authorization barriers. That suggestion does not mean choosing cheaper care automatically. Instead, it means exploring medically appropriate options that move faster through administrative systems.

Why Prior Authorization Denials Are Up — and Which Patients Are Hit the Hardest
Image Source: Unsplash.com

What Comes Next? The Future of Approval Battles in Healthcare

Policy experts expect prior authorization debate to continue growing because healthcare technology, specialty drugs, and aging populations keep expanding medical demand. Some reform proposals focus on transparency rules requiring insurers to explain denial reasoning more clearly. Others push for faster turnaround standards so clinical decisions do not stall patient care.

Technology might eventually help. Artificial intelligence review systems may evaluate clinical records faster, but regulators and medical professionals still worry about algorithmic bias and oversimplified decision logic. Future approval systems must balance speed, fairness, and clinical accuracy if they want public trust.

Healthcare feels personal because illness touches real lives, not just statistics. When authorization delays happen, someone misses medication, postpones therapy, or waits with worry. That emotional weight explains why the denial conversation keeps getting attention in policy meetings and community clinics alike.

Faster Care, Smarter Rules, and Less Waiting Around

Prior authorization denial growth reflects a complicated healthcare environment where cost control, medical innovation, and patient access collide. Some datasets show denial activity climbing in certain segments, though numbers vary across insurers and service types. Patients receiving specialty therapy, chronic disease treatment, and advanced diagnostic care feel the biggest impact when approvals slow down.

Have you or someone close to you ever experienced treatment delays because of insurance approval, and how did that situation feel in the middle of everything else happening in life? We want to hear everything you want to share in our comments section below.

You May Also Like…

Expense Spike: 8 Healthcare Costs That Hit Harder in Later Life

Navigating Coverage: Can You Rely on the Guilty Party’s Insurance If You’re Uninsured?

Why Home Insurance Claims Can Raise Premiums Without Payouts

Insurance Just Stopped Paying for These Routine Health Supplies — Check Your Plan Immediately

Expense Spike: 8 Healthcare Costs That Hit Harder in Later Life